ImmunoGen Reports Recent Progress and 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Nasdaq climbs as chip and AI-linked stocks bounce back
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Brent crude edges lower, even after Houthi attacks on Saudi infrastructure
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
Immunogen (IMGN) Tops Q4 EPS by 26c, Offers Q1 Guidance
February 12, 2021 6:32 AM ESTImmunogen (NASDAQ: IMGN) reported Q4 EPS of $0.16, $0.26 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $85.8 million versus the consensus estimate of $37.09 million.
GUIDANCE:
Immunogen sees Q1 2021 revenue of $65-75 million, versus the consensus of $53.1... More



